#advanced pancreatic cancer market size

[industrynewsupdates]

Enteral Feeding Devices Market Key Drivers and Emerging Trends 2024-2030

The global enteral feeding devices market size was valued at USD 4.3 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 5.0% from 2024 to 2030. 

Growing geriatric population has resulted in increased incidences of diabetes, severe pancreatitis, and other gastrointestinal diseases, which aids market growth. Adoption of the “Feed Early Enteral Diet Adequately for Maximum Effect” (FEED ME) protocol in surgical trauma ICUs in the U.S. enables subsidies on these devices. Technological advancements such as the introduction of tri-funnel replacement G-tubes and J-tubes with reverse balloon designs are also expected to aid in growth during the forecast period.

Gather more insights about the market drivers, restrains and growth of the Enteral Feeding Devices Market

Numerous NCBI studies suggest that people over 65 years pose a higher risk of developing chronic illnesses including Parkinson’s and nervous system disorders. The global population aged 60 years and older is expected to increase from around 1 billion in 2020 to about 1.4 billion in 2030 and is expected to double by 2050 to reach around 2.1 billion. The number of elderly patients with critical illnesses has increased significantly over the past few years. The risk of malnutrition and frailty among the geriatric population with comorbidities, such as stroke, depression, and dementia, is much higher, mainly owing to various age-related changes in body composition and muscle mass. This results in a reduced ability to perform Activities of Daily Living (ADLs), thereby increasing the risk of falls or injuries.

Enteral Feeding Devices Market Segmentation

Grand View Research, Inc. has segmented the global enteral feeding devices market report based on product, age group, indication, end-use, and region:

Product Outlook (Revenue, USD Million, 2018 - 2030)

• Giving Set

• Enteral Feeding Pump

• Percutaneous Endoscopic Gastrostomy Device

• Low Profile Gastrostomy Device

• Nasogastric Tube

• Gastrostomy Tube

Age Group Outlook (Revenue, USD Million, 2018 - 2030)

• Adults 

• Pediatrics

Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Alzheimer’s

• Nutrition Deficiency

• Cancer Care

• Diabetes

• Chronic Kidney Diseases

• Orphan Diseases

• Dysphagia

• Pain Management

• Malabsorption/GI Disorder/Diarrhea

• Others

End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

o Cardiology

o Neurology

o Critical Care (ICU)

o Oncology

o Others

• Home Care

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o U.K.

o Germany

o France

o Spain `          

o Italy

o Russia

o Sweden

o Norway

o Denmark

• Asia Pacific

o China

o Japan

o India

o South Korea

o Australia

o Thailand

o Singapore

• Latin America

o Brazil

o Mexico

o Argentina

• MEA

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global surgical drills market size was estimated at USD 1.27 billion in 2023 and is projected to grow at a CAGR of 5.5% from 2024 to 2030.

• The global ophthalmic ultrasound devices market size was valued at USD 590.9 million in 2023 and is projected to grow at a CAGR of 5.7% from 2024 to 2030.

Key Companies & Market Share Insights

The market players are focusing on product development, new technological advancements, and other initiatives to strengthen their market position.

Key Enteral Feeding Devices Companies:

• Conmed Corporation

• C.R.Bard

• Cook Medical

• Boston Scientific Corporation

• Moog Inc.

• Fresenius Kabi AG

• Danone Medical Nutrition

• Kimberly-Clark

• Abbott Nutrition

• B Braun Melsungen AG

• Avanos Medical, Inc.

• Cardinal Health

• Applied Medical Technology, Inc.

• Vygon India

• Fidmi Medical

• ALCOR Scientific

• Amsino International, Inc.

Recent Developments

• In September 2023, Cardinal Health launched Kangaroo OMNI enteral feeding pump, intended to give patients undergoing enteral feeding more options to suit their individual needs over the course of their enteral feeding journey.

• In August 2023, Cardinal Health launched its next-generation NTrainerTM System 2.0, a medical device intended to shorten the length of stay in the neonatal intensive care unit (NICU) for premature and newborn infants by assisting them in developing the oral coordination skills necessary for the transition to independent feeding more quickly. The NTrainerTM System gives parents confidence in their newborns' progress and potential for success after discharge by giving clinicians the objective data they need to monitor an infant's development of pre-feeding skills through real-time assessment technology.

Order a free sample PDF of the Enteral Feeding Devices Market Intelligence Study, published by Grand View Research.

[trendingreportz]

Cancer Immunotherapy Market - Forecast(2024 - 2030)

Cancer Immunotherapy Market Overview

The Cancer Immunotherapy Market Size is estimated to reach $152.6 billion by 2028 and it is poised to grow at a CAGR of 14.7% over the forecast period of 2023-2028. Cancer immunotherapy is a rapidly growing form of cancer treatment, which is designed to use the body’s own immune system to attack and prevent cancer cells from growing and forming. Immunotherapy carries immense market potential with several pharmaceutical industry companies actively working towards getting FDA approval. Some of the common forms of cancer immunotherapy types are monoclonal antibodies, immunomodulators, cancer vaccines, oncolytic viral therapies and cell therapy. A significant increase in the incidence of various cancer types rightly aids in the growth of the market, as new players are trying to fund various clinical research for advanced treatment. According to World Health Organisation (WHO), Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. A growing clinical base substantiated by significant investments from private and public players forms a moderate to high industry outlook for the Cancer Immunotherapy Market.

Cancer Immunotherapy Market Report Coverage

The report: “Cancer Immunotherapy Market Forecast (2023-2028)" by IndustryARC, covers an in-depth analysis of the following segments in the Cancer Immunotherapy Market.

By Type: Immune Checkpoint Inhibitors, T-cell Transfer Therapy, Monoclonal Antibodies, Treatment Vaccines and Immune System Modulators.

By Cancer: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer and Others.

By Route of Administration: Intravenous, Oral, Topical and Intravesical.

By Geography: North America (the U.S., Canada and Mexico), Europe (Germany, Uthe UK, France, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan India, South Korea, Australia and New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and the Rest of the World (the Middle East and Africa).

Request Sample

Key Takeaways

Geographically, North America held a dominant market share in 2022. It is due to a plethora of market players providing extensive research and development services along with a nuanced and favorable environment for pharmaceutical finances. However, Asia-Pacific is expected to offer lucrative growth opportunities over the forecast period of 2023-2028.

A growing population base of cancer across the region supplemented by ailing immunotherapies as a mode to tackle cancer aids market growth. However, extensive usage of other cancer treatments along with the high cost associated with immunotherapies impede the market growth.

A detailed analysis of strengths, weaknesses, opportunities and threats would be provided in the Cancer Immunotherapy Market Report.

Cancer Immunotherapy Market Segment Analysis - by Type

Cancer Immunotherapy Market based on type can be further segmented into Immune Checkpoint Inhibitors, T-cell Transfer Therapy, Monoclonal Antibodies, Treatment Vaccines and Immune System Modulators. Monoclonal Antibodies held a dominant market share in 2022 and are estimated to be the fastest-growing type, with a CAGR of 15.9% over the forecast period of 2023-2028. Monoclonal antibodies flag cancer cells, triggers cell-membrane destruction, block cell growth, prevents blood vessel growth and various other function in resolving cancer. This form of treatment methodology is highly prescribed by doctors across the countries due to higher specificity and better cost control along with a safety profile. Moreover, this segment provides a targeted approach that rightly aids market growth. Moreover, as per a recent statement of Bristol Myers Squibb, around a 5% increase in revenues from Opdivo and Yervooy was reported in Q1 2022 against Q1 2021.

Inquiry Before Buying

Cancer Immunotherapy Market Segment Analysis - by Cancer

The Cancer Immunotherapy Market based on cancer type can be further segmented into Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer and Others. Lung Cancer held a dominant market share in 2022. It is owing to the high prevalence of this cancer type and the availability and effectiveness of immunotherapy to aid. As per the American Cancer Society, nearly 236,000 new lung cancer cases would be diagnosed in the U.S. in 2022 with high prevalence in older people than younger generations. However, Breast Cancer is estimated to be the fastest-growing cancer type, with a CAGR of 15.7% over the forecast period of 2023-2028. As per BreastCancer.Org, nearly 1 in 8 women in the U.S. would develop cancer each year. Critically, the rampant utilization of drugs such as dostarlimab and pembrolizumab as immune checkpoint inhibitors would aid market growth.

Cancer Immunotherapy Market Segment Analysis - by Geography

North America held a dominant market share of nearly 43% in 2022. This is owing to the presence of a large number of companies. Also, various strategic initiatives are undertaken by both private and public players to eradicate cancer. Active drug regularization from leading authorities allows for the launch in commercial settings which rapidly aids market growth. As per Cancer Statistics Canada 2021, nearly 229,200 cancer cases were diagnosed in the country, with an incidence of 2 in 5 Canadians developing cancer over a lifetime. However, Asia-Pacific is expected to offer lucrative growth opportunities over the forecast period of 2023-2028 owing to significant development in regions like Korea, Japan and India which would aid the market participation.

Schedule a Call

Cancer Immunotherapy Market Drivers

Substantial Case Growth in a Variety of Cancer Types:

The proliferation of cancer can start in almost any organ of the body and turn into a malignant form of the disease in no time. As per WHO, cancer is the second leading cause of death globally, with nearly one in six deaths in 2019 alone. Some of the common forms of cancer in men recorded are lung, prostate, colorectal, stomach and liver cancer, whilst breast, colorectal, lung and cervical cancer were the most recorded in women. As per WHO 2020, nearly 2.26 million cases of breast cancer were diagnosed, amongst various other forms of cancer. The usage of immunotherapy rightly aids in market growth.

Substantiated Research and Development Activities Pertinent to Immunotherapy:

A high focus on the development of immunotherapy as a form of treatment for cancer is seen in leading countries, especially, the HDE (Highly Developed Economies). As per Cancer Research Institute UK, nearly $400 million is invested by the organization each year for the prevention, diagnosis and treatment of cancer. Similarly, in 2022, nearly $13 million was granted to Stanford Scientists by U.S. National Cancer Institute and Cancer Research UK for Cancer Treatment. Furthermore, rampant clinical research trials using e-tools have successfully aided in the deployment of immunotherapy as a treatment form. Lastly, around 13 antibody therapeutical drugs were granted approval from 2019-2021 (January) within the EU and the U.S.

Cancer Immunotherapy Market Challenges

High Prevalence of Alternate Treatment Methodologies for Cancer along with Significant Price Challenges:

As per Cancer.Gov, immunotherapy drugs have received wide recognition across the treatment class. However, it is not as widely used as surgery, chemotherapy or radiation therapy. As per Cancer Research UK, nearly 45% of treatment cases for cancer in the United Kingdom opt for surgery; 28% for chemotherapy and nearly 27% for radiotherapy. Furthermore, the cost of utilizing immunotherapy as a treatment method is highly expensive. For example, CAR-T Therapy costs above $475,000 per patient (Kymirah). Similarly, monoclonal antibodies for Nivolumab are $6580 per infusion. These factors hamper the market growth.

Buy Now

Key Market Players

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Cancer Immunotherapy Industry. The top 10 companies in the Cancer Immunotherapy Market are:

Pfizer Inc

Astra Zeneca

Merck and Co

F-Hoffman-La Roche

Bristol Myers Squibb Company

Novartis AG

 Lily

Johnson and Johnson

 Immunocore

BioNTech

Recent Developments

In October 2022, Researchers from the University of Rhode Island and Yale University demonstrated the efficacy of a promising new approach to deliver immunotherapy agents to fight cancer. The approach is known as the Stimulator of Interferon Gene Agonist to an acid-seeking molecule called pH-low insertion peptide.

In October 2022, the FDA approved a new immunotherapy drug for advanced liver cancer. The drug is known as IMJUDO. It is for use in the combination immunotherapy regimen for adults with HCC or Hepatocellular Carcinoma Cancer.

In February 2022, BioNTech and MEDIGENE announced a global collaboration to advance T-cell Receptor Immunotherapies against Cancer. As per the agreement, MEDIGENE would receive EUR 26 million upfront from BioNTech under research funding.

[tamanna31]

New Study: 2024-2030 In Vitro Diagnostics Market Trend and Forecast Report

In Vitro Diagnostics Industry Overview

The global in vitro diagnostics (IVD) market size was estimated at USD 77.92 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2030. The growth can be attributed to increasing adoption of IVD owing to a rise in the incidence of infectious and chronic diseases. The development of automated IVD systems for laboratories and hospitals to provide efficient, accurate, and error-free diagnoses is expected to fuel market growth. The rising number of IVD products being launched by key players is also fueling market growth. For instance, in November 2023, ARUP Laboratories received a CE mark from EU-IVDR for AAV5 DetectCDx, a companion diagnostic to select the eligibility of severe hemophilia A-affected patients for BioMarin’s new gene therapy, Roctavian.

Gather more insights about the market drivers, restrains and growth of the In Vitro Diagnostics Market

Technological advancements in terms of accuracy, portability, and cost-effectiveness are expected to be one of the high-impact rendering drivers of this market. Introduction of novel and highly accurate clinical laboratory tests is boosting the adoption of novel IVD tests worldwide. In June 2023, Toray Industries, Inc. received marketing approval from Japan’s Ministry of Health, Labour and Welfare for its Toray APOA2-iTQ used to diagnose pancreatic cancer. Moreover, in March 2023, Abbott received U.S. FDA clearance for its novel laboratory Traumatic Brain Injury (TBI) blood test in the U.S. Increasing approvals of IVD tests for life-threatening diseases are expected to create new opportunities in the untapped market.

Key players in the market undertake various strategies to strengthen their position and offer their customers diverse, technologically advanced & innovative products. New product launches and partnerships are the most prominently adopted by companies to attract more customers. For instance, in March 2023, BD received 510(k) clearance for BD Vaginal Panel on the BD COR System to detect infectious causes of vaginitis. In August 2023, the Precision Medicine Centre (PMC) formed a partnership with the Regional Molecular Diagnostic Service (RMDS) to implement genomic technology for the diagnosis of cancer in Northern Ireland.

Favorable initiatives undertaken by government and non-government bodies to improve overall healthcare services are anticipated to increase market growth. In October 2023, the WHO published the Essential Diagnostics List (EDL), a comprehensive list of IVD products that helps countries make decisions regarding diagnostic tools. It provides evidence-based recommendations and ensures the accessibility of essential products for target people. Moreover, in August 2023, the Africa CDC collaborated with the Africa Development Agency-New Partnership for Africa's Development (AUDA-NEPAD) to increase access to diagnostic tests across Africa. Such initiatives are expected to boost market growth.

A rise in the geriatric population and growth in knowledge regarding early testing have led to a surge in the number of regular check-ups, as a majority of deaths due to infections and chronic conditions occur in the population aged over 75 years. As per the Office for Budget Responsibility, UK, healthcare costs have risen exponentially, which can create economic pressure on nations with rapidly growing geriatric population. However, this expenditure is anticipated to translate positively for the IVD industry, driving market growth.

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

• The global point of care infectious disease testing market size was valued at USD 11.40 billion in 2023 and is projected to grow at a CAGR of 4.3% from 2024 to 2030.

• The global transplant diagnostics market size was valued at USD 5.97 billion in 2023 and is projected to grow at a CAGR of 7.3% from 2024 to 2030.

Key Companies & Market Share Insights

Some of the key players operating in the in vitro diagnostics market include F. Hoffmann-La Roche Ltd.; Abbott; Quest Diagnostics Inc.; and Danaher. Market players are adopting various strategies, such as new product launches, mergers & acquisitions, and partnerships, to strengthen their product portfolios and offer diverse technologically advanced & innovative products.

Llusern Scientific, Biocartis Group NV, ARUP Laboratories, Veracyte, and Exact Sciences Corp are some of the emerging market participants in the market. Emerging companies are actively involved in developing novel and accurate IVD testing products to improve overall health services. Moreover, these companies are collaborating with research institutes, government bodies, and global leaders to increase the range of their products in potential markets.

Key In Vitro Diagnostics (IVD) Companies

Abbott

bioMérieux SA

QuidelOrtho Corporation

Siemens Healthineers AG

Bio-Rad Laboratories, Inc.

Qiagen

Sysmex Corporation

Charles River Laboratories

Quest Diagnostics Incorporated

Agilent Technologies, Inc.

Danaher Corporation

BD

F. Hoffmann-La Roche Ltd

Recent Developments

In December 2023, ARUP Laboratories and Medicover collaborated to provide diagnostic and healthcare services in Europe. ARUP Laboratories has developed AAV5 DetectCDx in collaboration with BioMarin Pharmaceutical Inc. to select therapies for severe hemophilia A patients

In November 2023, Veracyte joined Illumina to develop molecular tests for decentralized IVD applications. Companies are focusing on the development of Prosigna breast cancer and Percepta nasal swab tests of Veracyte

In October 2023, Promega Corporation announced its plan to develop and commercialize companion diagnostics kits with GSK Plc to identify cancer patients with MSI-H solid tumors

In February 2023, Unilabs announced investing over USD 200 million in Siemens Healthineers' technology and acquiring more than 400 laboratory analyzers to strengthen its laboratory infrastructure

In February 2023, F. Hoffmann-La Roche Ltd. collaborated with Janssen Biotech Inc. to develop companion diagnostics for targeted therapies. Companion diagnostic technologies include digital pathology, NGS, PCR, immunoassays, and immunohistochemistry

Order a free sample PDF of the In Vitro Diagnostics Market Intelligence Study, published by Grand View Research.

[heathcareforallworld]

Analyzing the Growth of the Pancreatic Cancer Diagnosis Market to 2032

Pancreatic cancer remains one of the most lethal forms of cancer, with a high mortality rate due to its typically late diagnosis and aggressive nature. Advances in diagnostic technologies, however, are providing hope for earlier detection and improved outcomes. This article explores the pancreatic cancer diagnosis market, covering market size, share, industry trends, and forecast up to 2032. We will delve into market segmentation and regional analysis to provide a comprehensive overview of the market dynamics.

Market Overview

The global pancreatic cancer diagnosis market has been growing steadily, driven by the increasing incidence of pancreatic cancer and advancements in diagnostic technologies. Pancreatic cancer diagnosis Market Size was estimated at 3.64 (USD Billion) in 2023. The Pancreatic Cancer Diagnosis Market Industry is expected to grow from 3.81(USD Billion) in 2024 to 5.6 (USD Billion) by 2032. The pancreatic cancer diagnosis Market CAGR (growth rate) is expected to be around 4.92% during the forecast period (2024 - 2032).

Market Segmentation

Understanding the segmentation of the pancreatic cancer diagnosis market is crucial for identifying growth opportunities and tailoring strategies to meet specific needs. The market can be segmented based on diagnostic method, end-user, and region.

By Diagnostic Method:

Imaging Tests: Includes CT scans, MRI, and endoscopic ultrasound, which are commonly used for detecting and staging pancreatic cancer.

Biopsy: Tissue sampling techniques such as fine-needle aspiration and core needle biopsy are critical for confirming diagnosis.

Blood Tests: Biomarkers like CA 19-9 and genetic tests are becoming increasingly important for early detection and monitoring.

Molecular Diagnostics: Advanced techniques such as next-generation sequencing (NGS) and liquid biopsy are gaining traction for their accuracy and non-invasive nature.

By End-User:

Hospitals: The primary setting for comprehensive diagnostic procedures and treatment planning.

Diagnostic Laboratories: Specialized facilities offering advanced molecular and genetic testing.

Research Institutes: Contributing to the development of new diagnostic tools and methods through clinical trials and studies.

By Region:

North America: Leading the market with significant investments in healthcare infrastructure and research.

Europe: Strong market presence driven by robust healthcare systems and increasing cancer awareness.

Asia-Pacific: Expected to witness the highest growth rate due to improving healthcare access and rising cancer prevalence.

Latin America: Moderate growth with increasing awareness and improving diagnostic capabilities.

Middle East and Africa: Emerging market with potential growth driven by investments in healthcare and diagnostic technologies.

Regional Analysis

The pancreatic cancer diagnosis market exhibits significant regional variations, influenced by healthcare infrastructure, prevalence of the disease, and economic conditions.

North America:

The largest market for pancreatic cancer diagnosis, driven by high incidence rates and advanced healthcare facilities.

The U.S. dominates the region with substantial funding for cancer research and high adoption of advanced diagnostic technologies.

Europe:

Holds a significant market share with countries like Germany, France, and the U.K. leading in terms of diagnosis and treatment capabilities.

Government initiatives and public health programs aimed at early cancer detection contribute to market growth.

Asia-Pacific:

Expected to experience the fastest growth during the forecast period.

Rapid urbanization, increasing healthcare expenditure, and rising awareness about cancer screening are key drivers.

Latin America:

Moderate growth supported by improving healthcare infrastructure and increasing awareness about pancreatic cancer.

Brazil and Mexico are the major contributors to the market in this region.

Middle East and Africa:

The market is in the nascent stage but shows potential for growth due to increasing healthcare investments and rising incidence of cancer.

Efforts to improve diagnostic capabilities and cancer care services are underway.

Industry Trends

Several trends are shaping the pancreatic cancer diagnosis market, reflecting advancements in technology, healthcare practices, and patient preferences.

Rise of Molecular Diagnostics:

Molecular diagnostics, including NGS and liquid biopsy, are becoming more prominent due to their precision and non-invasive nature.

These technologies enable earlier detection and personalized treatment approaches.

Integration of Artificial Intelligence (AI):

AI and machine learning are being integrated into diagnostic imaging and data analysis to improve accuracy and speed.

AI algorithms assist in detecting subtle changes in imaging studies that may indicate early stages of pancreatic cancer.

Emphasis on Biomarkers:

Research into biomarkers like CA 19-9 and new genetic markers is expanding, providing tools for early detection and monitoring disease progression.

Biomarker-based tests are becoming more refined and widely available.

Advancements in Imaging Technologies:

Enhanced imaging techniques, such as high-resolution CT and MRI, provide better visualization of pancreatic tumors.

Endoscopic ultrasound (EUS) is becoming a standard tool for detailed imaging and biopsy.

Focus on Early Detection:

Public health initiatives and screening programs are increasingly focusing on early detection to improve survival rates.

Education and awareness campaigns aim to encourage individuals at high risk to undergo regular screening.

Telemedicine and Remote Diagnostics:

The adoption of telemedicine platforms is facilitating remote consultations and diagnostics, improving access to care.

Remote diagnostic tools and mobile health applications support patient monitoring and follow-up.

Market Forecast

The pancreatic cancer diagnosis market is expected to grow significantly over the next decade. Key factors driving this growth include:

Increasing Incidence of Pancreatic Cancer:

The rising global burden of pancreatic cancer, partly due to aging populations and lifestyle factors, fuels the demand for diagnostic solutions.

Improved understanding of genetic predispositions and risk factors contributes to the identification of high-risk individuals.

Technological Advancements:

Continuous innovation in diagnostic technologies, including molecular diagnostics, AI integration, and advanced imaging, enhances the market.

Research and development activities are likely to yield new, more effective diagnostic tools.

Rising Healthcare Expenditure:

Increased spending on healthcare, particularly in emerging economies, supports market growth.

Investments in healthcare infrastructure and cancer research are critical drivers.

Growing Awareness and Screening Programs:

Public health campaigns and screening programs promote early detection, which is crucial for improving outcomes.

Efforts to educate the public and healthcare providers about the importance of early diagnosis are gaining momentum.

Conclusion

The pancreatic cancer diagnosis market is assured of substantial growth, driven by increasing incidence rates, technological advancements, and evolving healthcare practices. With diverse diagnostic methods and significant regional variations, the market offers numerous opportunities for stakeholders. As the global focus on early cancer detection intensifies, the demand for effective and innovative diagnostic solutions will continue to rise, making the pancreatic cancer diagnosis market a critical component of cancer care strategies worldwide.

[credenceresearchdotblog]

The endoscopic ultrasound (EUS) needle market is projected to grow from USD 380.26 million in 2023 to USD 573.92 million by 2032, at a CAGR of 4.68%.Endoscopic Ultrasound (EUS) has become an indispensable tool in modern gastroenterology, blending endoscopy and ultrasound to provide detailed images and facilitate fine-needle aspiration (FNA) or biopsy of lesions within or adjacent to the gastrointestinal tract. EUS needles, pivotal to this procedure, have witnessed significant market growth owing to their critical role in diagnosing and staging gastrointestinal and other cancers. This article explores the key dynamics, trends, and future outlook of the EUS needles market.

Browse the full report at https://www.credenceresearch.com/report/endoscopic-ultrasound-eus-needles-market

Market Dynamics

Growing Prevalence of Gastrointestinal Diseases

The increasing incidence of gastrointestinal disorders, including pancreatic, gastric, and colorectal cancers, has driven the demand for EUS procedures. The ability of EUS to provide detailed images and facilitate targeted biopsies has made it a preferred diagnostic tool. This rising prevalence is a primary driver of the EUS needles market.

Technological Advancements

Technological innovations have significantly enhanced the safety, efficacy, and accuracy of EUS procedures. The development of needles with improved designs, such as the introduction of needles with echogenic tips, has improved visibility and accuracy during procedures. Additionally, the advent of fine-needle biopsy (FNB) needles has expanded the utility of EUS beyond aspiration, enabling histological examination.

Increasing Adoption of Minimally Invasive Procedures

The healthcare industry’s shift towards minimally invasive procedures is another critical factor propelling the EUS needles market. EUS is less invasive compared to traditional surgical methods, resulting in reduced patient recovery time, lower risk of complications, and cost savings. This trend aligns with the broader move towards minimally invasive diagnostics and therapeutics in the medical field.

Competitive Landscape

The EUS needles market is highly competitive, with key players focusing on product innovation, strategic collaborations, and mergers and acquisitions to strengthen their market position. Some of the prominent players include Olympus Corporation, Cook Medical, Medtronic, and Boston Scientific Corporation. These companies are investing in research and development to introduce advanced products and expand their product portfolios.

Future Outlook

The EUS needles market is poised for substantial growth in the coming years. The increasing prevalence of gastrointestinal diseases, technological advancements, and the growing adoption of minimally invasive procedures are expected to drive market expansion. Additionally, ongoing research and development activities aimed at improving the efficacy and safety of EUS needles will further fuel market growth.

Key Players

ACE Medical Devices Pvt. Ltd.

Boston Scientific Corporation

Cook Medical (Cook Group Incorporated)

CONMED Corporation

Endo-Flex GmbH

Fujifilm Holdings Corporation

Medi-Globe GmbH

Medtronic plc

Olympus Corporation

PENTAX Medical (Hoya Corporation)

ROCAMED

Sterylab S.r.l.

TaeWoong Medical Co., Ltd.

Wilson-Cook Medical Inc. (Cook Medical)

Xlumena, Inc. (Boston Scientific Corporation)

Others

Segmentations:

By Type

Aspiration Needles

Biopsy Needles

By Application

Enteral Needles

Bronchial Needles

By End-user

Hospital

Ambulatory Surgical Centers

Specialty Clinics

By Indication

Oncology

Gastroenterology

Pulmonology

Urology

Others

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

France

The U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of Middle East and Africa

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[deshpandeisha]

Transforming Veterinary Care: The Power of Electrosurgery

The global veterinary electrosurgery market size is expected to reach USD 919.3 Million at a steady revenue CAGR of 6.9% in 2030, according to the latest analysis by Emergen Research. One of the primary driving factors leading to revenue growth of this market is increase in the companion animal population. Pets are increasingly seen as companions or even family members. 

Electrosurgery harnesses the power of high-frequency electrical current to precisely cut, coagulate, and dissect tissue during surgical procedures. This technology offers veterinarians several advantages, including:

Precision and Control: Electrosurgical devices allow veterinarians to make precise incisions and control bleeding more effectively than traditional methods, leading to faster surgeries and reduced recovery times for patients.

Minimized Tissue Trauma: By minimizing physical trauma to surrounding tissues, electrosurgery helps mitigate post-operative pain and inflammation, promoting a quicker return to normal activities for animals.

Versatility: From routine procedures like spays and neuters to more complex surgeries, electrosurgery adapts to various veterinary applications, enhancing procedural flexibility and outcomes.

Sample Report@ https://www.emergenresearch.com/request-sample/1464

Reduced Risk of Complications: The ability to seal blood vessels as tissue is cut reduces the risk of hemorrhage and infection, contributing to overall surgical safety.

Enhanced Healing: Efficient tissue sealing and minimal tissue damage support faster healing times, enabling pets to recover swiftly and return home sooner.

As veterinary care continues to advance, electrosurgery stands at the forefront, empowering veterinarians to provide safer, more efficient surgeries with improved outcomes for their patients. Embracing these technological innovations not only elevates the standard of care but also reaffirms our commitment to the well-being and health of our beloved animal companions.

About Us:

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Visit for More Insights: https://www.emergenresearch.com/insights

Explore Our Custom Intelligence services | Growth Consulting Services

Trending Titles: Geocell Market | Pancreatic Cancer Treatment Market

Latest Report:  Ceramic Tiles Market | Life Science Analytics Market

[industryforecastnews]

In Vitro Diagnostics Market Size To Reach $101.58 Billion By 2030

In Vitro Diagnostic Market Growth & Trends

The global in vitro diagnostics market size is expected to reach USD 101.58 billion by 2030, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 4.4% over the forecast period driven by the increasing geriatric population, COVID-19 pandemic, and technological advancements in diagnostics that are supporting its adoption. Technological advancements in terms of portability, accuracy, and cost-effectiveness are projected to be one of the high-impact rendering drivers. Technological advancements were further accelerated by the launch of COVID-19 IVD diagnostics and enhanced the adoption of instruments and consumables for technologies, such as PCR. Competitors in the market are increasingly adopting agreement and partnership strategies to maintain a constant flow of business for manufacturers & diagnostics for users.

These agreements are also a result of the harsh price containment strategies for government laboratories, which lowers the price in government settings. For instance, in April 2021, the Italian subsidiary of Seegene, Inc. received a USD 108.25 million tenders for public procurement for the supply of extraction reagents, as well as 7.15 million SARS-CoV-2 diagnostic tests. However, it increases the multiparty nature and complexity of the supply chain. The high prevalence of cancer and Cardiovascular Diseases (CVDs) globally is anticipated to drive diagnostic innovation to facilitate early diagnosis and meet the constantly evolving needs of consumers. Novel technologies, such as plasmonic PCR, are anticipated to commercially enter the market during the forecast period, influencing the business of existing products adversely.

Technological advancements in terms of accuracy, portability, and cost-effectiveness are expected to be one of the high-impact rendering drivers of this market. Introduction of novel and highly accurate clinical laboratory tests is boosting the adoption of novel IVD tests worldwide. In June 2023, Toray Industries, Inc. received marketing approval from Japan’s Ministry of Health, Labour and Welfare for its Toray APOA2-iTQ used to diagnose pancreatic cancer. Moreover, in March 2023, Abbott received U.S. FDA clearance for its novel laboratory Traumatic Brain Injury (TBI) blood test in the U.S. Increasing approvals of IVD tests for life-threatening diseases are expected to create new opportunities in the untapped market.

Key players in the market undertake various strategies to strengthen their position and offer their customers diverse, technologically advanced & innovative products. New product launches and partnerships are the most prominently adopted by companies to attract more customers. For instance, in March 2023, BD received 510(k) clearance for BD Vaginal Panel on the BD COR System to detect infectious causes of vaginitis. In August 2023, the Precision Medicine Centre (PMC) formed a partnership with the Regional Molecular Diagnostic Service (RMDS) to implement genomic technology for the diagnosis of cancer in Northern Ireland.

Request a free sample copy or view the report summary: In Vitro Diagnostics Market Report

In Vitro Diagnostics Market Report Highlights

Molecular diagnostics is anticipated to grow at the fastest CAGR from 2024 to 2030 owing to the rising adoption and usage rate

Reagents held the largest market share owing to the surge in demand for genetic testing and enhanced availability of technologically advanced diagnostic tests in lower and middle-income countries with unmet clinical needs

The infectious diseases application segment held the largest market share owing to the large volume of testing for infectious diseases globally

North America dominated the global market in 2023 owing to the high demand for novel technologies, a large pool of key players, high prevalence of diseases, and advanced healthcare infrastructure

In Vitro Diagnostics Market Segmentation

Grand View Research has segmented the global in vitro diagnostics (IVD) market report based on product, technology, application, end-use, test location, and region:

IVD Product Outlook (Revenue, USD Million, 2018 - 2030)

Instruments

Reagents

Services

IVD Technology Outlook (Revenue, USD Million, 2018 - 2030)

Immunoassay

Instruments

Reagents

Services

Hematology

Instruments

Reagents

Services

Clinical Chemistry

Instruments

Reagents

Services

Molecular Diagnostics

Instruments

Reagents

Services

Coagulation

Instruments

Reagents

Services

Microbiology

Instruments

Reagents

Services

Others

Instruments

Reagents

Services

IVD Application Outlook (Revenue, USD Million, 2018 - 2030)

Infectious Diseases

Diabetes

Oncology

Cardiology

Nephrology

Autoimmune Diseases

Drug Testing

Others

IVD Test Location Outlook (Revenue, USD Million, 2018 - 2030)

Point of Care

Home-care

Others

IVD End-use Outlook (Revenue, USD Million, 2018 - 2030)

Hospitals

Laboratory

Home-care

Others

IVD Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Russia

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

South Korea

Australia

Thailand

Singapore

Latin America

Brazil

Mexico

Argentina

Middle East and Africa (MEA)

South Africa

Saudi Arabia

UAE

Kuwait

List of Key Players of In Vitro Diagnostics (IVD) Market

Abbott

bioMérieux SA

QuidelOrtho Corporation

Siemens Healthineers AG

Bio-Rad Laboratories, Inc.

Qiagen

Sysmex Corporation

Charles River Laboratories

Quest Diagnostics Incorporated

Agilent Technologies, Inc.

Danaher Corporation

BD

F. Hoffmann-La Roche Ltd.

Browse Full Report: In Vitro Diagnostics Market Report

[simranmakhija1]

Cell-Based Healing: Accelerating Success in Stem Cell Therapies

The endoscopic ultrasound (EUS) needles market is experiencing notable growth and innovation, driven by advancements in endoscopic technology, increasing prevalence of gastrointestinal disorders, and expanding applications of minimally invasive diagnostic and therapeutic procedures. Endoscopic ultrasound needles play a crucial role in facilitating tissue sampling, fine-needle aspiration (FNA), and injection therapies during EUS procedures, providing clinicians with valuable diagnostic information and enabling targeted treatments for various conditions.

Get a free Sample: https://www.marketdigits.com/request/sample/4683 

One of the primary drivers behind the growth of the endoscopic ultrasound needles market is the rising incidence of gastrointestinal diseases, including pancreatic cancer, gastrointestinal stromal tumors (GISTs), and pancreatic cysts. EUS-guided procedures, such as FNA and fine-needle biopsy (FNB), are essential for obtaining tissue samples from suspicious lesions within the gastrointestinal tract, pancreas, and adjacent organs, aiding in the diagnosis and staging of these diseases. As the demand for accurate and timely diagnosis of gastrointestinal malignancies continues to increase, so does the need for high-quality EUS needles that can reliably collect tissue samples for pathological analysis.

Global Endoscopic Ultrasound Needles Market Research Report 2023 renders deep perception of the key regional market status of the Endoscopic Ultrasound Needles Market Industry on a global level that primarily aims the core regions which comprises of continents like Europe, North America, and Asia and the key countries such as United States, Germany, China and Japan.

Moreover, technological advancements in EUS needle design and construction have expanded the capabilities and applications of these devices, driving innovation and market growth. Manufacturers are developing needles with thinner gauge sizes, enhanced flexibility, and improved visualization features to optimize tissue sampling and increase diagnostic yield. Additionally, the introduction of novel needle coatings, such as hydrophilic coatings and echo-enhancing coatings, helps to improve needle maneuverability, enhance visualization under ultrasound guidance, and reduce the risk of adverse events during EUS procedures.

Furthermore, the growing adoption of EUS-guided therapeutic interventions, such as drainage procedures, ablation therapies, and drug delivery, is driving demand for specialized needles designed for these applications. EUS-guided fine-needle injection (FNI) allows for precise delivery of therapeutic agents, such as chemotherapy, radiofrequency ablation, and biologic agents, directly into targeted lesions under ultrasound guidance. As clinicians continue to explore and expand the therapeutic capabilities of EUS, there is a growing need for innovative needle technologies that enable safe and effective delivery of therapeutic agents to achieve optimal patient outcomes.

Additionally, the increasing adoption of advanced imaging modalities, such as contrast-enhanced EUS and elastography, is further driving demand for specialized needles that can facilitate these procedures. Contrast-enhanced EUS allows for improved visualization and characterization of vascular structures and lesions within the gastrointestinal tract, pancreas, and other organs, enhancing diagnostic accuracy and treatment planning. Elastography, on the other hand, provides information about tissue stiffness and elasticity, aiding in the differentiation between benign and malignant lesions. As these imaging modalities become more integrated into routine clinical practice, the demand for compatible EUS needles is expected to grow accordingly.

However, despite the significant growth opportunities in the endoscopic ultrasound needles market, several challenges and considerations remain. These include concerns about needle-related complications, such as bleeding, perforation, and infection, as well as the need for standardized guidelines and training programs to ensure safe and effective use of EUS needles. Addressing these challenges will require collaboration among clinicians, manufacturers, and regulatory agencies to develop evidence-based practices and quality standards for EUS-guided procedures.

In conclusion, the endoscopic ultrasound needles market is poised for continued growth and innovation, driven by the increasing demand for minimally invasive diagnostic and therapeutic procedures in gastroenterology and oncology. With ongoing advancements in needle design, imaging technology, and procedural techniques, EUS needles are expected to play an increasingly important role in the diagnosis and management of gastrointestinal diseases, ultimately improving patient outcomes and quality of life.

[datahorizzon-research1]

Cancer Diagnostics Market on Track for Remarkable Year of Growth

The Cancer Diagnostics Market, valued at USD 138.2 Billion in 2022, is poised to reach USD 279.7 Billion by 2032, with a robust CAGR of 7.4%.

This market is undergoing significant growth and evolution driven by various factors. Firstly, advancements in technology, particularly in molecular diagnostics and imaging techniques, have transformed cancer diagnosis, enabling more precise and timely detection of the disease. Molecular diagnostic methods like polymerase chain reaction (PCR) and next-generation sequencing (NGS) have bolstered the capacity to identify specific genetic mutations and biomarkers linked to various cancer types, facilitating tailored treatment approaches.

The growth of the cancer diagnostics Market is influenced by several factors, including:

· Technological advancements: Innovations in molecular diagnostics, imaging techniques, and artificial intelligence enhance the accuracy and efficiency of cancer detection.

· Rising cancer prevalence: Increasing incidence rates globally drive the demand for diagnostic tests and screening programs.

· Emphasis on early detection: Healthcare initiatives and awareness campaigns promote early diagnosis, improving patient outcomes and driving market growth.

· Personalized medicine: Tailored treatment approaches based on genetic profiling and biomarker analysis increase the demand for diagnostic tools that enable precision medicine.

· Regulatory landscape: Regulatory approvals and reimbursement policies impact the adoption of new diagnostic technologies and tests.

· Collaboration and partnerships: Collaboration between industry players, research institutions, and healthcare providers accelerates innovation and market expansion.

Top Companies are:

· GE Healthcare

· Abbott

· F. Hoffmann-La Roche Ltd.

· Qiagen N.V.

· BD

· Siemens Healthcare GmbH

· Quest Diagnostics

· Thermo Fisher Scientific, Inc.

· Hologic, Inc.

· Koninklijke Philips N.V. (Philips)

· Illumina, Inc.

Market Segmentations:

By Product- Consumables, Instruments

By Technology- IVD Testing, Imaging, Biopsy Technique

By Screening- Laboratory Tests, Genetic Tests, Petroleum Refining, Endoscopy, Biopsy, Others

By Application- Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer, Skin Cancer, Blood Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, Ovarian Cancer, Others

For Further Information Regarding this Report: Ask For Discount:

Regional Analysis

North America is poised to maintain its dominance in the cancer diagnostics market, bolstered by its well-established healthcare infrastructure and significant contributions to the sector. The United States stands as the largest contributor, owing to its advanced healthcare system and substantial investments in cancer research and diagnostics. Moreover, the region’s market growth is fueled by the escalating incidence of cancer. For instance, the American Cancer Society estimates approximately 1.9 million new cancer cases and expects around 0.61 million fatalities in 2022.

Following North America, Europe emerges as the second-largest market for cancer diagnostics, with countries like Germany, France, and the United Kingdom holding considerable market shares. The region benefits from robust healthcare systems, government initiatives, and extensive research and development activities. According to research conducted by the University of Milan, the European Union is expected to witness around 1.2 million cancer deaths in 2022, highlighting the significant impact of the disease in the region.

Competitive Landscape:

In the competitive landscape of the cancer diagnostics market, numerous players vie for prominence through a spectrum of innovative solutions, strategic collaborations, and expansive market initiatives. Leading the forefront are established giants like Abbott Laboratories, Roche Diagnostics, and Thermo Fisher Scientific, renowned for their diverse portfolios encompassing molecular diagnostics, imaging technologies, and companion diagnostics. Siemens Healthineers and Bio-Rad Laboratories also wield significant influence with their advanced diagnostic imaging and molecular assay offerings. Additionally, Illumina, Qiagen N.V., and Hologic, Inc. play pivotal roles, leveraging their expertise in genomics, molecular diagnostics, and women’s health diagnostics, respectively, to address the multifaceted challenges of cancer detection and management.

Key Highlights Of the Report:

1. The report delivers thorough Market analysis, furnishing valuable insights to guide strategic decision-making.

2. The comprehensive research outlined in the study enhances the depth of your presentations and marketing strategies.

3. By offering crucial insights into key market competitors, the study empowers businesses with a strategic edge.

4. It delivers a precise assessment of evolving market dynamics, ensuring readers stay abreast of the latest industry trends.

5. With meticulous breakdowns of various market niches, the report facilitates informed decision-making processes.

The Report Answers Questions Such As:

· How is the cancer diagnostics market expected to grow in the future?

· What is the current market size and projected value for the cancer diagnostics market?

· What factors are fueling demand in the cancer diagnostics market?

· Which segment leads the industry?

· What investment opportunities show potential in the market?

About DataHorizzon Research:

DataHorizzon is a market research and advisory company that assists organizations across the globe in formulating growth strategies for changing business dynamics. Its offerings include consulting services across enterprises and business insights to make actionable decisions. DHR’s comprehensive research methodology for predicting long-term and sustainable trends in the market facilitates complex decisions for organizations.

[blog-site-for-market-research]

Future Outlook of the Cancer Diagnostics Market: Insights and Analysis

Market Overview –

The size of the cancer diagnostics market was estimated at USD 160.2 billion in 2021 and is expected to increase at a compound annual growth rate (CAGR) of 6.70% from USD 170.9 billion in 2022 to USD 269.1 billion by 2030.

The cancer diagnostics market is evolving, with a notable focus on multiple myeloma diagnosis. Advanced screening methods and diagnostic technologies are enhancing early detection rates for this complex cancer. As awareness grows and personalized medicine gains traction, the demand for accurate and efficient diagnostic tools continues to drive market growth in cancer diagnostics, particularly for multiple myeloma.

The cancer diagnostics market is a vital component of the healthcare sector focused on detecting, diagnosing, and monitoring various types of cancer. It encompasses a wide range of diagnostic tests, imaging techniques, and screening tools aimed at early detection and accurate diagnosis of cancer. This market is driven by factors such as the increasing incidence of cancer globally, advancements in diagnostic technologies, and growing awareness about the importance of early detection for better treatment outcomes.

One of the primary drivers of the cancer diagnostics market is the rising prevalence of cancer, fueled by factors like aging populations, unhealthy lifestyles, environmental factors, and genetic predispositions. Early detection plays a crucial role in improving patient survival rates and reducing the burden of cancer on healthcare systems, driving the demand for innovative diagnostic solutions.

Moreover, advancements in molecular biology, genomics, and proteomics have revolutionized cancer diagnostics, enabling the development of more sensitive and specific tests for early detection, prognostication, and treatment selection. Techniques such as next-generation sequencing, liquid biopsy, and molecular imaging have enhanced the accuracy and precision of cancer diagnosis, paving the way for personalized medicine approaches.

The COVID-19 pandemic has underscored the importance of resilient healthcare systems and the need for robust diagnostic capabilities. While the pandemic initially disrupted cancer screenings and diagnostics due to resource reallocation and healthcare system strains, the focus on improving diagnostic infrastructure and telemedicine solutions has accelerated innovation in the cancer diagnostics market.

However, challenges such as the high cost of diagnostic tests, reimbursement issues, and disparities in access to healthcare remain significant concerns for market stakeholders. Nonetheless, with ongoing research and collaborations aimed at advancing diagnostic technologies and improving patient outcomes, the cancer diagnostics market is poised for continued growth in the coming years, offering new hope in the fight against cancer.

Segmentation –

The global cancer diagnostics market has been segmented on the basis of types, application, and end user. Based on type, the global cancer diagnostics market has been segmented into biopsy based, endoscopy based, imaging procedure, tumor cancer diagnostics, and others. Based on application, the global cancer diagnostics market has been segmented into lung cancer, breast cancer, colorectal cancer, cervical cancer, prostate cancer, skin cancer, blood cancer, kidney cancer, liver cancer, pancreatic cancer, and others. Based on end user, the global cancer diagnostics market has been segmented into diagnostic center, clinic, hospital, research institutes, and others.

Regional Analysis –

The cancer diagnostics market varies regionally due to differences in healthcare infrastructure, screening programs, and prevalence of risk factors. North America leads with advanced diagnostic technologies and widespread cancer screening initiatives. Europe follows suit, with a focus on early detection and personalized medicine. In Asia-Pacific, the market is driven by increasing cancer incidence rates and improving healthcare access. Latin America and Africa face challenges such as limited access to diagnostic facilities but show potential for market growth with improving healthcare systems. Market players must tailor their diagnostic solutions to meet regional needs, considering factors like affordability, accessibility, and disease prevalence.

Key Players –

Cancer diagnostics companies include Exact Sciences Corporation, Arquer Diagnostics Ltd, BioMark Diagnostics Inc., Biotheranostics, Agilent Technologies, Thermo Fisher Scientific, Illumina, Becton Dickinson and Company (BD), GE Healthcare, QIAGEN N.V., and Abbott Laboratories.

Related Reports –

Steam Autoclave

Diagnostic Imaging

Neonatal Thermoregulation

Immunotherapy Drugs

For more information visit at MarketResearchFuture

[meghanester]

Leucovorin Calcium Market Size and Share, Growth by a Robust CAGR during 2023 – 2035

Research Nester published a report titled “Leucovorin Calcium Market: Global Demand Analysis & Opportunity Outlook 2035” which delivers detailed overview of the global leucovorin calcium market in terms of market segmentation by graft type, end-user, and by region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

The global leucovorin calcium market is estimated to grow at a robust CAGR over the forecast period, i.e., 2023 – 2035. The market is segmented on the basis of end-user into hospital, retail pharmacies, specialty clinics, and others. out of which, the hospital segment is anticipated to hold the notable share over the forecast period. This can be attributed to the increasing cancer patient pool at hospitals, backed by the higher acceptance of hospitals and growing prevalence of cancer.

The global leucovorin calcium market is anticipated to grow on the back of increasing prevalence of cancer, especially pancreatic and colon-rectum cancer, along with the rising cancer awareness across the globe. Moreover, the high cancer mortality rate in the world, is further estimated to drive the market growth. According to the data by the World Health Organization (WHO), over 10 million people died due to cancer, while colon and rectum cancer alone caused 916,000 deaths in 2020.

Get a Sample PDF Brochure: https://www.researchnester.com/sample-request-4020

On the basis of geographical analysis, the global leucovorin calcium market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the North America region is projected to gain notable growth over the forecast period, owing to the high prevalence of cancer in the region, along with the high healthcare expenditure in the developed countries. As per the data by the U.S. Centers for Medicare & Medicaid Services, the national healthcare expenditure grew by 9.7% to USD 4.1 trillion in 2020.

The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.

Request for customization @ https://www.researchnester.com/customized-reports-4020

Rising Awareness for Cancer Treatment to Boost the Market Growth

With the advancement in technology and growing research activities, there is a surge in the availability for proficient cancer treatment methods. Moreover, the awareness regarding the rare colon-rectum cancer is also rising amongst people. As a result, the demand for treatment is also bound to increase, which is estimated to boost the market growth.

However, high cost of cancer treatment is expected to operate as key restraint to the growth of global leucovorin calcium market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global leucovorin calcium market which includes company profiling of PromoCell GmbH, Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Bayer AG, Abbott Laboratories, Merck & Co., Inc., Mylan N.V., Novartis International AG, and Pfizer Inc. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global leucovorin calcium market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.     

Obtain this Report @ https://www.researchnester.com/reports/leucovorin-calcium-market/4020

About Us

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: info@researchnester.com

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

[gauricmi]

Pancreatic Cancer Therapeutics and Diagnostic Market: Combating the Silent Killer

Market Overview: The global Pancreatic Cancer Therapeutics and Diagnostic Market is estimated to be valued at US$3,689.6 million in 2021. This market is expected to experience a significant growth rate of 7.4% CAGR over the forecast period of 2023-2028, according to a recent report published by Coherent Market Insights. Pancreatic cancer is one of the deadliest forms of cancer, and the need for effective therapeutics and diagnostics has never been greater. These products play a crucial role in early detection, accurate diagnosis, and personalized treatment, providing hope for patients and improving survival rates. Market Key Trends: One of the key trends in the Pancreatic Cancer Therapeutics and Diagnostic Market is the growing emphasis on targeted therapies. Advances in genomic profiling and molecular diagnostics have enabled the identification of specific genetic mutations and biomarkers associated with pancreatic cancer. This knowledge allows for the development of targeted therapies that focus on inhibiting these genetic abnormalities, leading to more precise and effective treatment options. For example, F Hoffmann-La Roche AG's targeted therapy, erlotinib, has shown promise in treating patients with EGFR-mutated pancreatic cancer. Porter's Analysis: - Threat of new entrants: The high barriers to entry, such as stringent regulatory requirements and the need for substantial investments in research and development, make it challenging for new players to enter the market. - Bargaining power of buyers: As pancreatic cancer is a life-threatening disease with limited treatment options, buyers have minimal bargaining power and are willing to pay a premium for effective therapeutics and diagnostics. - Bargaining power of suppliers: The suppliers of raw materials and components for manufacturing pancreatic cancer therapeutics and diagnostic products have moderate bargaining power due to the availability of alternative suppliers in the market. - Threat of new substitutes: Currently, there are limited alternatives to therapeutics and diagnostics for pancreatic cancer. However, ongoing research in immunotherapy and gene therapy may pose potential future substitutes. - Competitive rivalry: The market is highly competitive, with key players like Merck KgaA, AstraZeneca PLC, and Novartis AG vying for market share. Intense competition drives innovation, leading to the development of novel treatments and diagnostic technologies. Key Takeaways: Paragraph 1: The global Pancreatic Cancer Therapeutics and Diagnostic Market Size is expected to witness high growth, exhibiting a CAGR of 7.4% over the forecast period. The increasing prevalence of pancreatic cancer, coupled with advancements in targeted therapies, is driving market growth. For instance, the rising incidence of pancreatic cancer, along with the growing geriatric population and lifestyle changes, contributes to market expansion. Paragraph 2: In terms of regional analysis, North America is anticipated to dominate the global market, owing to factors such as increasing healthcare infrastructure, early adoption of advanced diagnostic techniques, and favorable reimbursement policies. Furthermore, the Asia Pacific region is expected to witness the fastest growth, primarily due to a rise in awareness about pancreatic cancer, improving healthcare facilities, and increasing government initiatives.

[healthcaremarketfmi]

Cancer Gene Therapy Market 2022 New Technological Development Projecting Massive Growth till 2032

[300+ Pages Report] As per Future Market Insights’ latest revised industry analysis, the global cancer gene therapy market is projected to expand at a 10.1% CAGR over the forecast period, with the market size reaching US$ 5.3 Bn in 2032.

Gene therapy is a field of medicine that aims to cure or greatly improve the treatment of diseases that have few or no treatment options. Advanced-stage cancer and hematological illnesses make up a large share of gene therapy candidates. In addition to this, gene therapy is frequently used to treat rare or inherited diseases.

While gene therapy research is still in its early stages, firms are increasingly investing in the technology. A handful of products have recently received approval outside of Canada or are in the final stages of clinical trials.

Gene therapy is currently extremely expensive. Multi-stakeholder discussions about pricing and reimbursement management for these goods are required. To provide accessibility and quality of care, specialized manufacturing facilities, care centers, and doctors skilled to undertake specific procedures for such therapies are required.

The growth in the cancer gene therapy market is reliant on increasing awareness about health, the growing incidence of cancer, and the latest advancements in cancer gene therapy.

“Rising awareness regarding cancer gene therapy across emerging economies, along with favorable healthcare reimbursement plans in various countries will create opportunities for growth in the market over the forecast period,” says an FMI analyst.

Key Players :

Merck KGaA

Novartis AG

AstraZeneca Plc.

BIOCAD

Crinetics Pharmaceuticals, Inc.

EffRx Pharmaceuticals S.A.

Euroscreen S.A.

Vicore Pharma AB

Amgen

Bristol-Myers Squibb

Cell Genesys Inc.

Adaptimmune Therapeutics plc.

Achieve Life Science Inc.

BioCanCell Ltd.

Genelux Corporation

Advantagene Inc.,

GenVec Inc.

GlaxoSmithKline PLC

Amgen Inc.

For More Information: https://www.futuremarketinsights.com/reports/cancer-gene-therapy-market

Key Takeaways:

Based on therapy, the oncolytic virotherapy segment accounted for about 3% of the total market share in 2021.

In terms of indication, sales in the breast cancer segment are forecast to grow at a CAGR of 7% in the forecast period.

By service provider, demand in the hospitals segment will grow at a 9.3% CAGR through 2032.

The U.S. will dominate the North America cancer gene therapy market over the forecast period.

China will emerge as a lucrative pocket, accounting for 32.3% of the East Asia cancer gene therapy market share over the assessment period.

Demand in Germany is expected to increase at a 11.9% CAGR over the assessment period.

Competition Landscape

Acquisitions, partnerships, geographical recognition, and product launches are the key strategies adopted by leading players to increase the consumer base. For instance:

In March 2022, Novartis and Carisma Therapeutics agreed to collaborate on the development of HER 2 targeted CAR-M cell therapy.

A2 Biotherapeutics and Merck announced a collaboration in December 2020 to develop allogeneic cell therapy for solid tumor cancers.

Want More Insights

Future Market Insights brings a comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2032. The global cancer gene therapy market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the cancer gene therapy market segment based on therapy – (gene induced immunotherapy, oncolytic virotherapy, gene transfer, and others), by indication (breast cancer, ovarian cancer, liver cancer, pancreatic cancer, lung cancer, and prostate cancer), by service provider (hospitals, clinical research laboratory, and oncology institutes), across seven major regions.

About Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business.

By Therapy:

Gene Induced Immunotherapy

Oncolytic Virotherapy

Gene Transfer

Others

By Indication:

Breast Cancer

Ovarian Cancer

Liver Cancer

Pancreatic Cancer

Lung Cancer

Prostate Cancer

By Service Provider:

Hospitals

Clinical Research Laboratory

Oncology institutes

[reportsneww]

Histopathology Services Market to grow at a CAGR of over 5.4% from 2022 to 2030, reveals Growth Plus Reports

Newark, New Castle, USA - Growth Plus Reports' most recent study examines the Global Histopathology Services Market's production, prospective uses, demand, key companies, and SWOT analysis.

The Histopathology Services Market Report will help you determine the best distribution strategies for specific products and identify potential markets. In addition, the report examines the purchasing and supply patterns that impact the market. The Histopathology Services market research report provides insights into the limitations, market trends, prospects, drivers, and competition in the Histopathology Services sector.

You may get insights into the TOC, and Statistics for essential facts, information, trends, and competitive landscape information.

Download Free Sample Report Now @ https://www.growthplusreports.com/inquiry/request-sample/histopathology-services-market/8104

The following are the leading companies in the Global Histopathology Services market:

Cellular Pathology Services Limited

Acculabs Diagnostics UK Ltd.

Great Ormond Street Hospital (GOSH) Laboratory

HCA Laboratories UK

Sonic Healthcare Limited

Targos Molecular Pathology GmbH

Laboratoire Cerba

Spire Healthcare Group Plc

TPL Path Labs

Unilabs Group Services

Growth Plus Reports studies the key trends in each category and sub-segment of the Histopathology Services market, along with Global and regional projections from 2023 to 2031. Our research splits the market into product type and application segments.

SEGMENTATION

GLOBAL HISTOPATHOLOGY SERVICES MARKET- ANALYSIS & FORECAST, BY APPLICATION

Skin Tissue Biopsy

Liver Biopsy

Surgical Specimen

Breast Biopsy

Gastrointestinal Biopsy

Biopsy of Gynecological Cancers

Lung Biopsy

Testicular Biopsy

Pancreatic Biopsy

Others

GLOBAL HISTOPATHOLOGY SERVICES MARKET- ANALYSIS & FORECAST, BY END-USER

Diagnostic Laboratories and Reference Laboratories

Research Institutes

Others

For More Information or Query or Customization visit: https://www.growthplusreports.com/inquiry/customization/histopathology-services-market/8104

Companies may utilize Histopathology Services market report to get insights on market variables and any restraints that may affect the manufacturing of their product. Companies that are expanding abroad require thorough Global market research that includes real market data to assist with their marketing strategy. This Global market Histopathology Services industry study analyzes important market dynamics and provides in-depth information and statistics to help companies flourish. This research report on the Histopathology Services market takes advantage of advanced and professional approaches such as SWOT analysis and GRG Health's unique GrowthMIX strategy.

This report is useful in addressing various essential issues for market participants, while also supporting them in making investments and leveraging the market opportunities.

Histopathology Services Market TOC: https://www.growthplusreports.com/report/toc/histopathology-services-market/8104

Market segment by Region/Country including: –

-North America (United States, Canada and Mexico) -Europe (Germany, UK, France, Italy, Russia and Spain etc.) -Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.) -South America (Brazil, Argentina and Colombia etc.) -Middle East and Africa (South Africa, UAE and Saudi Arabia etc.)

QUICK BUY: https://www.growthplusreports.com/checkout-8104

Browse Latest Healthcare Reports:

MOG Antibody Associated Disorders Treatment Market Size, Share 2023 to 2031

Aortic Valve Replacement Devices Market Industry Analysis report to 2031 

Alveolar Soft Part Sarcoma Market size, share & trends Analysis report to 2031

Magnetic Resonance Imaging Equipment Market Developments

Facet Joint Injections Market Size ,Share & Regional Outlook to 2031

Health Telemetry Market size, Technology & Industry Analysis report to 2031

Blood Cancer Diagnostics Market Size, Share Industry Analysis to 2031

Smoking Cessation Apps Market size, share & trends Analysis report to 2031

Serotonin-Dopamine Activity Modulators Market Size, Share 2023 to 2031

[mysticalfungalaxy]

Non-Vascular Stents Market is expected to be valued at US$ 1.9 billion by 2032 | FMI

The Non-Vascular Stents Market is expected to grow at a CAGR of 4.5% over the anticipated timeframe. (2022 – 2032). In 2022, it is projected that the industry will be worth US$ 1.21 billion, and by 2032, it will be worth US$ 1.9 billion.

The global non-vascular stents market is expected to move forward in response to the growing demand for minimally-invasive procedures. Rising technological and material advancements are assisting in the development of specially designed stents for use in a variety of indications thereby fueling the overall non-vascular stents market growth.

To learn more about this report @ https://www.futuremarketinsights.com/reports/non-vascular-stents-market

Non-vascular stents use small, precise incisions, resulting in scars that are smaller and less visible than those left by traditional surgical techniques, putting the patient’s safety in jeopardy. Such surgery is associated with a faster recovery period, resulting in a shorter hospital stay for the patient, encouraging many to opt for the same.

Furthermore, patients are less likely to contract hospital-acquired illnesses like bloodstream infections and urinary tract infections if they stay in the hospital for a shorter period of time, in turn, propelling the demand for non-vascular stents.

The most visible and prominent factor spiking the sales of non-vascular stents is a surge in cases of chronic obstructive pulmonary disease (COPD), which is caused by smoking, lung cancer, tracheobronchial malacia, and chemical exposure.

Numerous innovations are taking place in the non-vascular stents market as new medical devices are developed to track gastrointestinal tract, urinary tract, and airway tract.

Non-vascular stents market trends are fostered by rising healthcare spending in developing countries, government and private insurance companies’ helpful medical reimbursement policies, and the proliferation of hospitals and ambulatory surgical centers.

The non-vascular stents market is segmented by product type and by region, where by product type, the market is divided into gastrointestinal stents, pulmonary stents, urological stents, and others.

Non-vascular implants are medical devices designed to keep open and support non-vascular structures within the body. Unlike vascular stents, which are used to treat blockages in blood vessels, non-vascular stents are used to treat a variety of conditions in other parts of the body.

Key Takeaways:

Based on product type, the urological stents segment is likely to dominate the non-vascular stents market with a CAGR of 4.3% through 2032.

The US non-vascular stents market is expected to capture a sizeable non-vascular stents market share accounting for around US$659.1 million by 2032.

By 2032, the UK non-vascular stents market is expected to be valued at US$ 80.6 million, growing at a CAGR of 3.3%.

With a CAGR of 3.6% during the forecast period, China non-vascular stents market size is predicted to be apprised at US$ 128.1 million by 2032.

The Japan non-vascular stents market, with a CAGR of 3.9%, is projected to garner a worth of US$ 109.8 million by 2032.

Key Players:

Medtronic plc.

Glaukos Corporation

Boston Scientific Corporation

ELLA – CS, s.r.o.

CONMED Corporation

Key Segments

By Product:

Gastrointestinal Stents

Biliary

Duodenal

Colonic

Pancreatic

Oesophageal Stents

Pulmonary Stents

Silicone Airway

Metallic Airway

Urological Stents

Others